Inhibikase Therapeutics Inc’s recently made public that its 10% Owner Sands Capital Life Sciences Pu acquired Company’s shares for reported $3.0 million on Nov 21 ’25. In the deal valued at $1.45 per share,2,068,965 shares were bought. As a result of this transaction, Sands Capital Life Sciences Pu now holds 13,018,965 shares worth roughly $20.18 million.
H.C. Wainwright downgraded its Inhibikase Therapeutics Inc [IKT] rating to a Neutral from a a Buy in a research note published recently.
Price Performance Review of IKT
On Monday, Inhibikase Therapeutics Inc [NASDAQ:IKT] saw its stock jump 4.03% to $1.55. Over the last five days, the stock has gained 1.97%. Inhibikase Therapeutics Inc shares have fallen nearly -21.72% since the year began. Nevertheless, the stocks have fallen -52.31% over the past one year. While a 52-week high of $4.20 was reached on 01/02/25, a 52-week low of $1.33 was recorded on 11/03/25.
Levels Of Support And Resistance For IKT Stock
The 24-hour chart illustrates a support level at 1.4833, which if violated will result in even more drops to 1.4167. On the upside, there is a resistance level at 1.6133. A further resistance level may holdings at 1.6767.
How much short interest is there in Inhibikase Therapeutics Inc?
A steep rise in short interest was recorded in Inhibikase Therapeutics Inc stocks on 2025-10-31, dropping by -0.45 million shares to a total of 3.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.48 million shares. There was a decline of -14.82%, which implies that there is a negative sentiment for the stock.
